Barry Datlof, the chief of business development and commercialization at the Office of Medical Technology Transfer (MTT), recently received the 2024 Department of Defense George F. Linsteadt Technology Transfer Achievement Award for his work on the Assistive Technology Transfer (AT2) program. The AT2 program aims to de-risk and commercialize first-generation biomedical technologies for military and civilian applications. Datlof accepted the award on behalf of the MTT team, recognizing their innovative ways of accelerating technology transfer within the DOD.
The MTT team’s accomplishments in technology transfer have generated over $20 million in revenue and $40 million in Cooperative Research and Development Agreements. The team has successfully licensed over 30 biomedical technologies, generating over $26 million in royalty income. This income is reinvested back into the AT2 program to support the development of new inventions, creating a feedback loop of success.
Datlof emphasizes the importance of teamwork and collaboration within the MTT office, highlighting the diverse expertise and willingness to take risks. As the MTT office looks towards the future, Datlof proposes the establishment of a DOD-wide “angel fund” to accelerate technology adoption. Additionally, the team is exploring digital marketplace technologies to enhance technology transfer processes.
Overall, the MTT team’s commitment to innovation and collaborative efforts in technology transfer has been recognized through the Linsteadt Award. As they continue their work in advancing military medical technology, Datlof and his team are focused on achieving impactful results and improving the lives of warfighters and the public.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.]